Residual Coronary Risk Factors Associated With Long-Term Clinical Outcomes in Patients With Coronary Artery Disease Treated With High- vs. Low-Dose Statin Therapy　― REAL-CAD Substudy ―-Reference-Cited by-同舟云学术

Residual Coronary Risk Factors Associated With Long-Term Clinical Outcomes in Patients With Coronary Artery Disease Treated With High- vs. Low-Dose Statin Therapy　― REAL-CAD Substudy ―

Published:2023-07-21 Issue: Volume: Page:
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Higuma Takumi¹,Akashi Yoshihiro J.²,Fukumoto Yoshihiro³,Obara Hitoshi⁴,Kakuma Tatsuyuki⁴,Asaumi Yasuhide⁵,Yasuda Satoshi⁶,Sakuma Ichiro⁷,Daida Hiroyuki⁸,Shimokawa Hiroaki⁹,Kimura Takeshi¹⁰,Iimuro Satoshi¹¹,Nagai Ryozo¹²

Affiliation:

1. Division of Cardiology, Department of Internal Medicine, Kawasaki Municipal Tama Hospital

2. Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine

3. Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine

4. Biostatistics Center, Kurume University

5. Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center

6. Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine

7. Caress Sapporo Hokko Memorial Clinic

8. Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine

9. Graduate School, International University of Health and Welfare

10. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

11. Innovation and Research Support Center, International University of Health and Welfare

12. Jichi Medical University

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-23-0134/_pdf

Reference31 articles.

1. 1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278, doi:10.1016/s0140-6736(05)67394-1.

2. 2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.

3. 3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307, doi:10.1056/nejm199511163332001.

4. 4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–1009, doi:10.1056/nejm199610033351401.

5. 5. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357, doi:10.1056/nejm199811053391902.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No standard modifiable cardiovascular risk factors in acute myocardial infarction: prevalence, pathophysiology, and prognosis;Cardiovascular Intervention and Therapeutics;2024-06-17

2. The Worst Combination for Coronary Artery Disease Under Strong-Statin Therapy Is Chronic Kidney Disease and Diabetes　― Non-Lipid Residual Risk Assessment From the REAL-CAD Study ―;Circulation Journal;2023-10-19